Tumor Lysis Syndrome After Treatment With Docetaxel for Non–Small-Cell Lung Cancer

Ajzensztejn, Daniel; Hegde, Vinayak; Lee, Siow Ming

doi:10.1200/jco.2005.02.8753

Cited by 17 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to note that all of the reported patients had evidence of metastatic disease. Five patients had adenocarcinoma, 10,11,13,14,17 two patients had squamous cell carcinoma, 15,16 and one patient had evidence of mixed NSCLC and SCLC. 12 Five patients developed TLS secondary to chemotherapy.…”

Section: Tumor Lysis Syndrome In Lung Cancersmentioning

confidence: 99%

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature

et al. 2014

View full text Add to dashboard Cite

Tumor lysis syndrome (TLS) is a potentially deadly complication of tumors or their treatment. This syndrome consists of a constellation of laboratory findings such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, known as laboratory TLS. When clinical complications such as seizures, acute renal failure, and cardiac dysrhythmias occur in patients with laboratory TLS, the syndrome is called clinical TLS. TLS is especially common in patients with hematological malignancies with rapid cellular turnover rates such as acute lymphocytic leukemia and Burkitt lymphoma, but is very rare in patients with solid tumors. Nevertheless, there are multiple reports in the literature on the occurrence of TLS in patients with solid tumors. In this review article, we summarize the current data on the occurrence of TLS in patients with solid tumors. We propose an algorithm of risk stratification and prevention of TLS in patients with solid cancers.

show abstract

Section: Tumor Lysis Syndrome In Lung Cancersmentioning

confidence: 99%

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature

et al. 2014

View full text Add to dashboard Cite

show abstract

“…According to the literature review, there have been 100 reported cases of TLS in patients with solid tumors from the first report in 1977 to 2011 (Table 1) (Figure 2), including small cell carcinomas [9, 20–30], squamous cell carcinomas [10, 11], adenocarcinomas of the lung [12, 31–33], mixed small cell and nonsmall cell lung carcinoma [34], gastrointestinal carcinomas [13–15, 35–42], hepatoblastomas [43, 44], hepatocellular carcinomas [15, 45–53], renal carcinomas [54–56], transitional cell carcinoma [57], prostate carcinomas [58–61], breast carcinomas [16, 30, 62–68], ovarian carcinomas [69, 70], endometrial carcinoma [71], vulva carcinomas [72, 73], thymomas [74, 75], melanomas [76–82], gestational trophoblastic neoplasia [83], germ cell tumors [17, 18, 64, 84, 85], neuroblastomas [86, 87], medulloblastomas [88, 89], and sarcomas [19, 90–93]. Most cases regarded as TLS in solid tumors were chemotherapy-induced, even though various other causes were pointed out for TLS in solid tumors as well [3] (Table 1) (Figure 1).…”

Section: Review Of the Literaturementioning

confidence: 99%

An Unusual Presentation of Tumor Lysis Syndrome in a Patient with Advanced Gastric Adenocarcinoma: Case Report and Literature Review

Vodopivec

Rubio

Fornoni

et al. 2012

Case Reports in Medicine

View full text Add to dashboard Cite

Tumor lysis syndrome (TLS) is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia in patients with a malignancy. When these laboratory abnormalities develop rapidly, clinical complications such as cardiac arrhythmias, acute renal failure, seizures, or death may occur. TLS is caused by rapid release of intracellular contents by dying tumor cells, a condition that is expected to be common in hematologic malignancies. However, TLS rarely occurs with solid tumors, and here we present the second chemotherapy-induced TLS in a patient with advanced gastric adenocarcinoma to be reported in the literature. We also provide information regarding the total cases of TLS in solid tumors reported from 1977 to present day. Our methodology involved identifying key articles from existing reviews of the literature and then using search terms from these citations in MEDLINE to find additional publications. We relied on a literature review published in 2003 by Baeksgaard et al., where they gathered all total 45 cases reported from 1977 to 2003. Then, we looked for new reported cases from 2004 to present day. All reports (case reports, brief reports, letters to editor, correspondence, reviews, journals, and short communications) identified through these searches were reviewed and included.

show abstract

“…These malignancies share the characteristics of a high proliferative rate, large tumor burden, or high sensitivity to cytotoxic therapy. [1][2][3][4][5] In some cases, tumor lysis syndrome can lead to acute renal failure and even death. The key to the management of tumor lysis syndrome includes awareness of its causes, identification of high-risk patients, implementation of appropriate prophylactic measures, vigilant monitoring of electrolyte levels in patients undergoing chemotherapy, and initiation of more active treatment measures when necessary.…”

mentioning

confidence: 99%